Social··Severity 6
AstraZeneca's Rare Drug Trial Failure Sends Shares Plunging
AstraZeneca Plc's shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart problems in patients with a rare disease. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)
Scenario chain
Probabilities below are model estimates based on the event chain, horizon, and indicators. They are not outcome guarantees, investment advice, or emergency instructions.
A
25%Эскалация
Forecast derived from cascade analysis. Watch confirmation indicators below.
Primary source: Bloomberg Markets
Checking access status…